USA

Emerging U.S. biotech company EpiVario, Inc. has highlighted preclinical research findings that could lead to a treatment approach for post-traumatic stress disorder (PTSD).  Published in Proceedings of the National Academy of Sciences (PNAS), and co-authored by the academic co-founders of EpiVario, the study demonstrates that fear memories can be controlled through the enzyme acetyl-CoA synthetase […]

U.S. clinical-stage biopharma company 89bio, Inc. has completed enrollment in ENLIVEN, the phase 2b trial of pegozafermin for the treatment of non-alcoholic steatohepatitis (NASH). “We are very pleased to have successfully completed enrollment of 219 total patients in ENLIVEN, a well-powered trial that builds on positive data demonstrating pegozafermin’s broad metabolic effects and favorable safety/tolerability […]